iSTAR Medical Receives European Market Approval for Glaucoma Implant MINIject

iSTAR Medical, a medtech company pioneering novel minimally-invasive implants for glaucoma surgery (MIGS), today announced that its breakthrough MIGS device, MINIject, has been approved in Europe for open-angle glaucoma patients. MINIject enables more patients to be effectively treated with MIGS because of its powerful and sustained performance combined with an excellent safety profile.

Glaucoma is the leading cause of irreversible blindness affecting around 100 million people worldwide.[1],2 MIGS represents the most promising and fastest-growing glaucoma therapy, due to its enhanced safety profile compared to traditional surgery. Data reported to date by iSTAR Medical across four trials in over 150 patients, consistently show that MINIject demonstrates a balance of powerful and sustained intra-ocular pressure (IOP) reduction with a positive safety profile.

MINIject’s powerful efficacy and safety make it optimal for treatment in a broader glaucoma population, meaning flexibility for use in a greater number of procedures. iSTAR Medical is now rolling out MINIject commercially in select regions across Europe and is delighted that its first commercial implantations have already taken place in Germany.

Michel Vanbrabant, CEO of iSTAR Medical, commented: “With today’s European approval, MINIject becomes the only commercially available MIGS device targeting the supraciliary space as a natural outflow pathway for IOP reduction. This is a major milestone for iSTAR Medical and our mission to bring truly next-generation MIGS devices to the glaucoma community. I want to thank our team, our investors, and our medical partners for their continued belief in a safer and better way to manage glaucoma by targeting the supraciliary space, with an implant powered by our proprietary STAR® material.”

Positive two-year results from iSTAR Medical’s STAR-II European trial were recently presented at the 125th American Academy of Ophthalmology (AAO) meeting in New Orleans, LA (USA) demonstrating a sustained powerful efficacy and safety outcome in patients with open-angle glaucoma, consistent with all MINIject trial outcomes to date.

Professor Dr. Burkhard Dick, Head of the Department of Ophthalmology at University Eye Hospital Bochum, Germany, and one of the MINIject STAR-II trial investigators, treated the first patient with MINIject after European approval. He commented: “I’m very pleased that I’m now able to offer the MINIject supraciliary device as a treatment option to my mild-to-moderate glaucoma patients, the first of which was treated successfully today,” he said. “Based on results so far, MINIject may open up new treatment paradigms for patients with glaucoma across Europe.”

David Stocker, VP Sales & Marketing at iSTAR Medical added: “The launch of our first product in Europe sets iSTAR Medical on a very promising trajectory for future value generation. With its unique product characteristics, MINIject has the potential to gain a significant share of the growing wider market for glaucoma treatments and amongst its peers in the MIGS segment. Our ambition is to make this novel MIGS solution available to a broad patient community and grow the organisation, our network and our international footprint to meet the size of the opportunity.”

Furthermore, MINIject is currently being investigated in iSTAR Medical’s pivotal STAR-V study, which was approved by the United States Food and Drug Administration (FDA) in July 2021, the results of which will be instrumental to gain commercial access for MINIject in the US market. The study will enrol over 350 patients with primary open-angle glaucoma.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version